GlobeNewsWire
18 Oct 2026, 21:00 UTC · 2h ago
Impact · against what's priced in
Disc Medicine is set to release Phase 3 topline results for bitopertin in EPP. While the announcement of the webcast is a standard procedural milestone, the actual market catalyst will be the data revealed tomorrow.
Scored by the NIS engine · methodology.
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Disc Medicine will host a webcast on October 19, 2026, to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP.
Newpress release dated Oct 18
More positive than 99% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Search tags
More positive than 54% of ticker scores this week
The company is announcing the upcoming release of Phase 3 trial results, which is a positive milestone but the actual data is not yet revealed.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
